In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Laboratory Corp. of America Holdings LH from Sell to Neutral, and raised the price target from $83.00 to $96.00.
In the report, Ro noted, “We now believe LH stands to benefit from a volume tailwind from ACA and pricing pressure should be manageable – driving our more positive outlook on LH shares. However we prefer DGX over LH, as wee see less margin upside and our current estimates already reflect considerably more aggressive share repurchase than DGX limiting upside outer year EPS estimates. Since adding LH to the Sell List on 11/18/12, the shares are +13% vs. the S&P 500 +17% given limited volume growth and pricing pressure. Over the past 12 months, LH is +5% vs. the S&P 500 +17%.”
Laboratory Corp. of America Holdings closed on Wednesday at $93.40.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in